clinical_trials

Isomab Review Clears Cancer, Eye Safety Fears for Angiogenic Heart Therapies

Nottingham – September 09, 2026 -- Isomab Ltd has published a systematic review showing no increased cancer or retinopathy risk from pro-angiogenic therapies for coronary artery disease, removing a two-decade safety barrier that has constrained development across the field.

Review of 636 patients finds malignancy rates below population norms

The analysis covered 11 clinical studies conducted between 2002 and 2024, spanning 636 patients with angina or peripheral artery disease -- 441 receiving pro-angiogenic therapy and 195 on placebo -- with follow-up periods ranging from two to 12 years. Mean malignancy incidence was 0.84 per 100 patient-years for the treatment group versus 0.72 for placebo, both figures falling below the age-matched population rate of 1.0 per 100 patient-years. Retinal events were rare in both cohorts and also below population benchmarks.

Mabwell's 9MW1911 Cuts Severe COPD Exacerbations by 100% at High Dose

Shanghai – September 08, 2026 -- Mabwell (688062.SH, 02493.HK) reported that its anti-ST2 monoclonal antibody 9MW1911 reduced the annualized rate of severe COPD exacerbations by 100% in the 900 mg dose group compared with placebo, according to Phase Ib/IIa data presented as a poster at the European Respiratory Society International Congress 2026 (ERS 2026).

Trial enrolled 80 COPD patients across four dose arms

The randomized, double-blind, placebo-controlled study (9MW1911-C03) enrolled 80 former smokers with moderate-to-severe COPD, randomizing participants to intravenous 9MW1911 at 100 mg, 300 mg, 600 mg, or 900 mg, or placebo, every four weeks. Most participants had blood eosinophil counts of 300 cells/μL or below.

Acepodia Wins FDA Clearance for Dual-Payload ADC ACE723 in Liver Cancer

Alameda, Calif. – September 08, 2026 -- Acepodia (6976: TT) said the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate, clearing the way for a Phase 1 clinical trial in unresectable or metastatic hepatocellular carcinoma (HCC).

FDA clearance advances first candidate from Acepodia's AD2C platform into human trials

ACE723 is built on Acepodia's proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform, which combines antibody engineering, medicinal chemistry and tumor biology to deliver two cytotoxic payloads to a single tumor-targeting antibody. The compound targets GPC3, a tumor-associated antigen frequently expressed in HCC tumor cells.

Texas Cardiac Arrhythmia Institute First US Site for New PFA Trial

Austin – September 07, 2026 -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center has become the first facility in the United States to enroll in a clinical trial evaluating a next-generation mapping and pulsed field ablation (PFA) system for patients with paroxysmal and persistent atrial fibrillation.

TCAI performs first procedure under global study leadership

Andrea Natale, M.D., executive medical director of TCAI and global principal investigator for the trial, conducted the first procedure using the new catheter system. The trial is designed to assess the safety and efficacy of the technology across both forms of atrial fibrillation, the most common cardiac arrhythmia, which affects millions of patients worldwide.